Medication info
Crechek 5 mg (Rosuvastatin Calcium)

Crechek 5 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle
Approval status
Active

MFDS item code 201400432 · Approved 2014.01.29 · Insurance code 645304820

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg per day. Elderly patients: No dosage adjustment is necessary. Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.
Child dose
Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily (there are no clinical data on administering doses higher than 20 mg to pediatric patients). The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary heart disease
  • stroke
  • myocardial infarction
View approved original text

This medication is used as an adjunctive therapy when diet and exercise are insufficient to control primary hypercholesterolemia and mixed hyperlipidemia in patients. It is also prescribed as an adjunctive therapy for patients with homozygous familial hypercholesterolemia. It helps lower total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, slowing the progression of atherosclerosis. Additionally, it is used as an adjunct therapy to reduce blood lipid levels in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia. It is also used to assist in dietary management for patients with primary dysbetalipoproteinemia and contributes to reducing the risk of stroke, myocardial infarction, and revascularization procedures in middle-aged and older patients at high risk for cardiovascular disease. Overall, it is a medication that helps improve cholesterol levels and cardiovascular disease risk factors.

How to take

Adult dose

Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg per day. Elderly patients: No dosage adjustment is necessary. Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.

Child dose

Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily (there are no clinical data on administering doses higher than 20 mg to pediatric patients). The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, individuals who are allergic to this medication, those with severely impaired liver function, those with muscle diseases, those taking certain immunosuppressants, individuals with severe renal impairment, pregnant or nursing women, and those with genetic issues such as lactose intolerance should not take this medication. Moreover, caution is warranted for patients with a history of excessive alcohol consumption or liver disease, and regular liver function tests should be conducted before and during treatment. In cases of conditions like hypothyroidism or nephrotic syndrome, it is advisable to treat those conditions before taking this medication. Myalgia or myopathy may occur during the use of this medication, and if any unusual muscle symptoms occur, medical personnel should be notified immediately. Especially if muscle-related symptoms coincide with significantly elevated muscle enzyme levels in blood tests, discontinuation of this medication is warranted. This medication may increase blood concentration when taken with certain drugs, raising the risk of muscle-related side effects. Therefore, if other medications are being taken, medical personnel must be informed. Special caution is required when used in conjunction with certain antivirals, immunosuppressants, and fibrate drugs. Women who are pregnant or may become pregnant must use appropriate contraception before taking this medication, and if pregnancy is confirmed, it should be discontinued immediately. Additionally, it is safer for nursing mothers to avoid this medication. In cases of overdose, there are no specific antidotes, so management based on symptoms and monitoring liver function and muscle enzymes is necessary. This medication is generally known not to significantly affect driving or machinery operation; however, caution is still advised as dizziness may occur infrequently. Finally, it is important to regularly monitor liver function and muscle condition during treatment with this medication, and to consult with medical personnel immediately if any unusual symptoms occur.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), fixed drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbance, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, elevated ALT, chest pain, muscle cramps, gout, erectile dysfunction, fatigue, numbness, dysesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, widespread pain, muscle cramps

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be kept between 1 and 30 degrees Celsius at room temperature, and it is advisable to avoid excessively hot or cold places.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.